{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T14:41:32Z","timestamp":1787755292124,"version":"build-2784847793"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T00:00:00Z","timestamp":1725667200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T00:00:00Z","timestamp":1725667200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270162"],"award-info":[{"award-number":["82270162"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270224"],"award-info":[{"award-number":["82270224"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Beijing Natural Science Foundation of China","award":["7222175"],"award-info":[{"award-number":["7222175"]}]},{"DOI":"10.13039\/501100005090","name":"Beijing Nova Program","doi-asserted-by":"publisher","award":["20230484407"],"award-info":[{"award-number":["20230484407"]}],"id":[{"id":"10.13039\/501100005090","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2021YFA1100904"],"award-info":[{"award-number":["2021YFA1100904"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Military medical support innovation and generate special program","award":["21WQ034"],"award-info":[{"award-number":["21WQ034"]}]},{"name":"Special Research Found for Health Protection","award":["21BJZ30"],"award-info":[{"award-number":["21BJZ30"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s00277-024-05972-w","type":"journal-article","created":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T06:02:12Z","timestamp":1725688932000},"page":"4707-4719","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Addition of ruxolitinib and decitabine to modified busulfan\/cyclophosphamide conditioning regimen for prophylaxis relapse in high-risk acute myeloid leukemia: the phase 2 prospective study"],"prefix":"10.1007","volume":"103","author":[{"given":"Yujun","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songhua","family":"Luan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangshu","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Dou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daihong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,7]]},"reference":[{"issue":"19","key":"5972_CR1","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1182\/blood.2020009471","volume":"137","author":"PD Lulla","year":"2021","unstructured":"Lulla PD, Naik S, Vasileiou S et al (2021) Clinical effects of administering leukemia-specific donor T cells to patients with AML\/MDS after allogeneic transplant. Blood 137(19):2585\u20132597. https:\/\/doi.org\/10.1182\/blood.2020009471","journal-title":"Blood"},{"issue":"5","key":"5972_CR2","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.bbmt.2017.12.794","volume":"24","author":"SB Tsai","year":"2018","unstructured":"Tsai SB, Rhodes J, Liu H et al (2018) Reduced-intensity allogeneic transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome using combined CD34-Selected Haploidentical Graft and a single umbilical cord unit compared with matched unrelated donor stem cells in older adults. Biol Blood Marrow Transpl 24(5):997\u20131004. https:\/\/doi.org\/10.1016\/j.bbmt.2017.12.794","journal-title":"Biol Blood Marrow Transpl"},{"issue":"1","key":"5972_CR3","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1182\/blood-2015-07-604546","volume":"127","author":"JJ Cornelissen","year":"2016","unstructured":"Cornelissen JJ, Blaise D (2016) Hematopoietic stem cell transplantation for patients with AML in first complete remission. Blood 127(1):62\u201370. https:\/\/doi.org\/10.1182\/blood-2015-07-604546","journal-title":"Blood"},{"issue":"11","key":"5972_CR4","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1002\/ajh.25620","volume":"94","author":"M Molica","year":"2019","unstructured":"Molica M, Breccia M, Foa R, Jabbour E, Kadia TM (2019) Maintenance therapy in AML: the past, the present and the future. Am J Hematol 94(11):1254\u20131265. https:\/\/doi.org\/10.1002\/ajh.25620","journal-title":"Am J Hematol"},{"issue":"36","key":"5972_CR5","doi-asserted-by":"publisher","first-page":"4249","DOI":"10.1200\/JCO.19.03277","volume":"38","author":"L Gao","year":"2020","unstructured":"Gao L, Zhang Y, Wang S et al (2020) Effect of rhG-CSF Combined with Decitabine Prophylaxis on Relapse of patients with high-risk MRD-Negative AML after HSCT: an Open-Label, Multicenter, Randomized Controlled Trial. J Clin Oncol 38(36):4249\u20134259. https:\/\/doi.org\/10.1200\/JCO.19.03277","journal-title":"J Clin Oncol"},{"issue":"12","key":"5972_CR6","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1200\/JCO.19.03011","volume":"38","author":"CS Hourigan","year":"2020","unstructured":"Hourigan CS, Dillon LW, Gui G et al (2020) Impact of conditioning intensity of allogeneic transplantation for Acute myeloid leukemia with genomic evidence of residual disease. J Clin Oncol 38(12):1273\u20131283. https:\/\/doi.org\/10.1200\/JCO.19.03011","journal-title":"J Clin Oncol"},{"issue":"7","key":"5972_CR7","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1038\/s41409-021-01238-5","volume":"56","author":"X Tang","year":"2021","unstructured":"Tang X, Valdez BC, Ma Y et al (2021) Low-dose decitabine as part of a modified Bu-Cy conditioning regimen improves survival in AML patients with active disease undergoing allogeneic hematopoietic stem cell transplantation. Bone Marrow Transpl 56(7):1674\u20131682. https:\/\/doi.org\/10.1038\/s41409-021-01238-5","journal-title":"Bone Marrow Transpl"},{"issue":"3","key":"5972_CR8","doi-asserted-by":"publisher","first-page":"e178","DOI":"10.1016\/S2352-3026(22)00375-1","volume":"10","author":"L Xuan","year":"2023","unstructured":"Xuan L, Dai M, Jiang E et al (2023) The effect of granulocyte-colony stimulating factor, decitabine, and busulfan-cyclophosphamide versus busulfan-cyclophosphamide conditioning on relapse in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia evolving from myelodysplastic syndrome undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised, phase 3 trial. Lancet Haematol 10(3):e178\u2013e190. https:\/\/doi.org\/10.1016\/S2352-3026(22)00375-1","journal-title":"Lancet Haematol"},{"issue":"12","key":"5972_CR9","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","volume":"363","author":"S Verstovsek","year":"2010","unstructured":"Verstovsek S, Kantarjian H, Mesa RA et al (2010) Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 363(12):1117\u20131127. https:\/\/doi.org\/10.1056\/NEJMoa1002028","journal-title":"N Engl J Med"},{"issue":"9","key":"5972_CR10","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1110557","volume":"366","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek S, Mesa RA, Gotlib J et al (2012) A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 366(9):799\u2013807. https:\/\/doi.org\/10.1056\/NEJMoa1110557","journal-title":"N Engl J Med"},{"key":"5972_CR11","doi-asserted-by":"publisher","first-page":"100634","DOI":"10.1016\/j.blre.2019.100634","volume":"40","author":"S Venugopal","year":"2020","unstructured":"Venugopal S, Bar-Natan M, Mascarenhas JO (2020) JAKs to STATs: a tantalizing therapeutic target in acute myeloid leukemia. Blood Rev 40:100634. https:\/\/doi.org\/10.1016\/j.blre.2019.100634","journal-title":"Blood Rev"},{"issue":"20","key":"5972_CR12","doi-asserted-by":"publisher","first-page":"4614","DOI":"10.1182\/blood-2011-12-400051","volume":"119","author":"A Eghtedar","year":"2012","unstructured":"Eghtedar A, Verstovsek S, Estrov Z et al (2012) Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia. Blood 119(20):4614\u20134618. https:\/\/doi.org\/10.1182\/blood-2011-12-400051","journal-title":"Blood"},{"issue":"18","key":"5972_CR13","doi-asserted-by":"publisher","first-page":"2826","DOI":"10.1182\/blood-2013-05-505735","volume":"123","author":"AM Cook","year":"2014","unstructured":"Cook AM, Li L, Ho Y et al (2014) Role of altered growth factor receptor-mediated JAK2 signaling in growth and maintenance of human acute myeloid leukemia stem cells. Blood 123(18):2826\u20132837. https:\/\/doi.org\/10.1182\/blood-2013-05-505735","journal-title":"Blood"},{"issue":"50","key":"5972_CR14","doi-asserted-by":"publisher","first-page":"E5401","DOI":"10.1073\/pnas.1407792111","volume":"111","author":"R Rampal","year":"2014","unstructured":"Rampal R, Ahn J, Abdel-Wahab O et al (2014) Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms. Proc Natl Acad Sci U S A 111(50):E5401\u2013E5410. https:\/\/doi.org\/10.1073\/pnas.1407792111","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"22","key":"5972_CR15","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1182\/blood-2018-03-785907","volume":"132","author":"O Odenike","year":"2018","unstructured":"Odenike O (2018) How I treat the blast phase of Philadelphia chromosome-negative myeloproliferative neoplasms. Blood 132(22):2339\u20132350. https:\/\/doi.org\/10.1182\/blood-2018-03-785907","journal-title":"Blood"},{"issue":"9","key":"5972_CR16","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1038\/s41375-020-0778-0","volume":"34","author":"P Bose","year":"2020","unstructured":"Bose P, Verstovsek S, Cortes JE et al (2020) A phase 1\/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia. Leukemia 34(9):2489\u20132492. https:\/\/doi.org\/10.1038\/s41375-020-0778-0","journal-title":"Leukemia"},{"issue":"20","key":"5972_CR17","doi-asserted-by":"publisher","first-page":"5246","DOI":"10.1182\/bloodadvances.2020002119","volume":"4","author":"JO Mascarenhas","year":"2020","unstructured":"Mascarenhas JO, Rampal RK, Kosiorek HE et al (2020) Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase. Blood Adv 4(20):5246\u20135256. https:\/\/doi.org\/10.1182\/bloodadvances.2020002119","journal-title":"Blood Adv"},{"issue":"4","key":"5972_CR18","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D et al (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129(4):424\u2013447. https:\/\/doi.org\/10.1182\/blood-2016-08-733196","journal-title":"Blood"},{"issue":"3","key":"5972_CR19","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1159\/000503095","volume":"12","author":"F Azam","year":"2019","unstructured":"Azam F, Latif MF, Farooq A et al (2019) Performance Status Assessment by using ECOG (Eastern Cooperative Oncology Group) score for Cancer patients by Oncology Healthcare professionals. Case Rep Oncol 12(3):728\u2013736. https:\/\/doi.org\/10.1159\/000503095","journal-title":"Case Rep Oncol"},{"issue":"12","key":"5972_CR20","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR et al (2022) Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140(12):1345\u20131377. https:\/\/doi.org\/10.1182\/blood.2022016867","journal-title":"Blood"},{"issue":"1","key":"5972_CR21","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s13045-021-01159-2","volume":"14","author":"X-H Zhang","year":"2021","unstructured":"Zhang X-H, Chen J, Han M-Z et al (2021) The consensus from the Chinese Society of Hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update. J Hematol Oncol 14(1):145. https:\/\/doi.org\/10.1186\/s13045-021-01159-2","journal-title":"J Hematol Oncol"},{"issue":"1","key":"5972_CR22","first-page":"75e","volume":"27","author":"C Hou","year":"2021","unstructured":"Hou C, Dou L, Jia M et al (2021) Ruxolitinib Combined with corticosteroids as First-Line therapy for Acute Graft-versus-host disease in Haploidentical Peripheral blood stem cell transplantation recipients. Transpl Cell Ther Jan 27(1):75e. 1-75.e10","journal-title":"Transpl Cell Ther Jan"},{"issue":"1","key":"5972_CR23","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","volume":"22","author":"AC Harris","year":"2016","unstructured":"Harris AC, Young R, Devine S et al (2016) International, Multicenter standardization of Acute Graft-versus-host Disease Clinical Data Collection: a report from the Mount Sinai Acute GVHD International Consortium. Biol Blood Marrow Transpl 22(1):4\u201310. https:\/\/doi.org\/10.1016\/j.bbmt.2015.09.001","journal-title":"Biol Blood Marrow Transpl"},{"issue":"24","key":"5972_CR24","doi-asserted-by":"publisher","first-page":"6714","DOI":"10.1182\/blood-2010-12-323824","volume":"117","author":"M Arora","year":"2011","unstructured":"Arora M, Klein JP, Weisdorf DJ et al (2011) Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis. Blood 117(24):6714\u20136720. https:\/\/doi.org\/10.1182\/blood-2010-12-323824","journal-title":"Blood"},{"issue":"4","key":"5972_CR25","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1053\/bbmt.2003.50026","volume":"9","author":"SJ Lee","year":"2003","unstructured":"Lee SJ, Vogelsang G, Flowers MED (2003) Chronic graft-versus-host disease. Biol Blood Marrow Transpl 9(4):215\u2013233. https:\/\/doi.org\/10.1053\/bbmt.2003.50026","journal-title":"Biol Blood Marrow Transpl"},{"issue":"12","key":"5972_CR26","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1182\/blood-2017-09-801498","volume":"131","author":"GJ Schuurhuis","year":"2018","unstructured":"Schuurhuis GJ, Heuser M, Freeman S et al (2018) Minimal\/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood 131(12):1275\u20131291. https:\/\/doi.org\/10.1182\/blood-2017-09-801498","journal-title":"Blood"},{"issue":"16","key":"5972_CR27","doi-asserted-by":"publisher","first-page":"3864","DOI":"10.1182\/bloodadvances.2020001904","volume":"4","author":"J Grimm","year":"2020","unstructured":"Grimm J, Jentzsch M, Bill M et al (2020) Prognostic impact of the ELN2017 risk classification in patients with AML receiving allogeneic transplantation. Blood Adv 4(16):3864\u20133874. https:\/\/doi.org\/10.1182\/bloodadvances.2020001904","journal-title":"Blood Adv"},{"issue":"11","key":"5972_CR28","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1016\/j.bbmt.2020.07.020","volume":"26","author":"E Rodr\u00edguez-Arbol\u00ed","year":"2020","unstructured":"Rodr\u00edguez-Arbol\u00ed E, Labopin M, Tischer J et al (2020) FLAMSA-Based reduced-intensity conditioning versus Myeloablative Conditioning in younger patients with Relapsed\/Refractory Acute myeloid leukemia with active disease at the time of allogeneic stem cell transplantation: an analysis from the Acute Leukemia Working Party of the European Society for Blood and marrow transplantation. Biol Blood Marrow Transpl 26(11):2165\u20132173. https:\/\/doi.org\/10.1016\/j.bbmt.2020.07.020","journal-title":"Biol Blood Marrow Transpl"},{"issue":"8","key":"5972_CR29","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1182\/blood-2015-04-639831","volume":"126","author":"SO Ciurea","year":"2015","unstructured":"Ciurea SO, Zhang M-J, Bacigalupo AA et al (2015) Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. Blood 126(8):1033\u20131040. https:\/\/doi.org\/10.1182\/blood-2015-04-639831","journal-title":"Blood"},{"issue":"7","key":"5972_CR30","doi-asserted-by":"publisher","first-page":"790","DOI":"10.4103\/0366-6999.228243","volume":"131","author":"L-P Dou","year":"2018","unstructured":"Dou L-P, Li H-H, Wang L et al (2018) Efficacy and safety of unmanipulated Haploidentical Related Donor Allogeneic Peripheral blood stem cell transplantation in patients with Relapsed\/Refractory Acute Myeloid Leukemia. Chin Med J (Engl) 131(7):790\u2013798. https:\/\/doi.org\/10.4103\/0366-6999.228243","journal-title":"Chin Med J (Engl)"},{"issue":"15","key":"5972_CR31","doi-asserted-by":"publisher","first-page":"4570","DOI":"10.1182\/bloodadvances.2022007168","volume":"6","author":"M Jentzsch","year":"2022","unstructured":"Jentzsch M, Bischof L, Backhaus D et al (2022) Impact of MRD status in patients with AML undergoing allogeneic stem cell transplantation in the first vs the second remission. Blood Adv 6(15):4570\u20134580. https:\/\/doi.org\/10.1182\/bloodadvances.2022007168","journal-title":"Blood Adv"},{"issue":"2","key":"5972_CR32","doi-asserted-by":"publisher","first-page":"601","DOI":"10.3390\/cancers4020601","volume":"4","author":"RM Grubovikj","year":"2012","unstructured":"Grubovikj RM, Alavi A, Koppel A, Territo M, Schiller GJ (2012) Minimal residual disease as a predictive factor for relapse after allogeneic hematopoietic stem cell transplant in adult patients with acute myeloid leukemia in first and second complete remission. Cancers (Basel) 4(2):601\u2013617. https:\/\/doi.org\/10.3390\/cancers4020601","journal-title":"Cancers (Basel)"},{"issue":"10","key":"5972_CR33","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1182\/blood-2013-06-506725","volume":"122","author":"RB Walter","year":"2013","unstructured":"Walter RB, Buckley SA, Pagel JM et al (2013) Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission. Blood 122(10):1813\u20131821. https:\/\/doi.org\/10.1182\/blood-2013-06-506725","journal-title":"Blood"},{"issue":"4","key":"5972_CR34","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1200\/JCO.2015.63.3826","volume":"34","author":"D Araki","year":"2016","unstructured":"Araki D, Wood BL, Othus M et al (2016) Allogeneic hematopoietic cell transplantation for Acute myeloid leukemia: time to move toward a minimal residual disease-based definition of complete remission? J Clin Oncol 34(4):329\u2013336. https:\/\/doi.org\/10.1200\/JCO.2015.63.3826","journal-title":"J Clin Oncol"},{"issue":"11","key":"5972_CR35","doi-asserted-by":"publisher","first-page":"3205","DOI":"10.1007\/s00277-023-05406-z","volume":"102","author":"S Jiang","year":"2023","unstructured":"Jiang S, Lu X, Wei R et al (2023) Salvage hematopoietic stem cell transplantation for patients with higher leukemia burden in relapsed or refractory acute myeloid leukemia: a ten-year study. Ann Hematol 102(11):3205\u20133216. https:\/\/doi.org\/10.1007\/s00277-023-05406-z","journal-title":"Ann Hematol"},{"issue":"7","key":"5972_CR36","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1182\/blood-2013-03-484642","volume":"122","author":"A Heine","year":"2013","unstructured":"Heine A, Held SAE, Daecke SN et al (2013) The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo. Blood 122(7):1192\u20131202. https:\/\/doi.org\/10.1182\/blood-2013-03-484642","journal-title":"Blood"},{"issue":"3","key":"5972_CR37","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMoa2033122","volume":"385","author":"R Zeiser","year":"2021","unstructured":"Zeiser R, Polverelli N, Ram R et al (2021) Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease. N Engl J Med 385(3):228\u2013238. https:\/\/doi.org\/10.1056\/NEJMoa2033122","journal-title":"N Engl J Med"},{"issue":"15","key":"5972_CR38","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1016\/S1470-2045(15)00200-4","volume":"16","author":"A Rambaldi","year":"2015","unstructured":"Rambaldi A, Grassi A, Masciulli A et al (2015) Busulfan plus Cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol 16(15):1525\u20131536. https:\/\/doi.org\/10.1016\/S1470-2045(15)00200-4","journal-title":"Lancet Oncol"},{"issue":"10","key":"5972_CR39","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1007\/s00277-015-2423-y","volume":"94","author":"J Tischer","year":"2015","unstructured":"Tischer J, Engel N, Fritsch S et al (2015) Virus infection in HLA-haploidentical hematopoietic stem cell transplantation: incidence in the context of immune recovery in two different transplantation settings. Ann Hematol 94(10):1677\u20131688. https:\/\/doi.org\/10.1007\/s00277-015-2423-y","journal-title":"Ann Hematol"},{"issue":"7","key":"5972_CR40","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1038\/s41409-018-0382-3","volume":"54","author":"J Yang","year":"2019","unstructured":"Yang J, Jiang J, Cai Y et al (2019) Low-dose anti-thymocyte globulin plus low-dose posttransplant cyclophosphamide as graft-versus-host disease prophylaxis in haploidentical peripheral blood stem cell transplantation combined with unrelated cord blood for patients with hematologic malignancies: a prospective, phase II study. Bone Marrow Transpl 54(7):1049\u20131057. https:\/\/doi.org\/10.1038\/s41409-018-0382-3","journal-title":"Bone Marrow Transpl"},{"key":"5972_CR41","doi-asserted-by":"publisher","first-page":"620891","DOI":"10.3389\/fimmu.2020.620891","volume":"11","author":"J-R Zhou","year":"2020","unstructured":"Zhou J-R, Shi D-Y, Wei R et al (2020) Co-reactivation of Cytomegalovirus and Epstein-Barr Virus was Associated with Poor Prognosis after allogeneic stem cell transplantation. Front Immunol 11:620891. https:\/\/doi.org\/10.3389\/fimmu.2020.620891","journal-title":"Front Immunol"},{"issue":"24","key":"5972_CR42","doi-asserted-by":"publisher","first-page":"5536","DOI":"10.1182\/bloodadvances.2021005566","volume":"5","author":"JS Garcia","year":"2021","unstructured":"Garcia JS, Kim HT, Murdock HM et al (2021) Adding venetoclax to fludarabine\/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active. Blood Adv 5(24):5536\u20135545. https:\/\/doi.org\/10.1182\/bloodadvances.2021005566","journal-title":"Blood Adv"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05972-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-05972-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05972-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T09:29:33Z","timestamp":1730712573000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-05972-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,7]]},"references-count":42,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["5972"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-05972-w","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,7]]},"assertion":[{"value":"14 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}